AdvisorShares Investments LLC Has $6.12 Million Stock Holdings in Stryker Corporation $SYK

AdvisorShares Investments LLC reduced its position in shares of Stryker Corporation (NYSE:SYK) by 8.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 18,632 shares of the medical technology company’s stock after selling 1,794 shares during the quarter. Stryker accounts for about 1.1% of AdvisorShares Investments LLC’s holdings, making the stock its 25th biggest position. AdvisorShares Investments LLC’s holdings in Stryker were worth $6,122,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new stake in Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new position in Stryker in the 2nd quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker during the second quarter valued at $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $326.41 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The company has a fifty day moving average of $309.80 and a 200-day moving average of $338.87. The firm has a market capitalization of $125.13 billion, a P/E ratio of 37.78, a P/E/G ratio of 2.09 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SYK has been the topic of several analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Leerink Partners lowered their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Evercore set a $355.00 target price on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.